Last reviewed · How we verify
14C-Quizartinib solution for infusion — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
14C-Quizartinib solution for infusion (14C-Quizartinib solution for infusion) — Daiichi Sankyo.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 14C-Quizartinib solution for infusion TARGET | 14C-Quizartinib solution for infusion | Daiichi Sankyo | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 14C-Quizartinib solution for infusion CI watch — RSS
- 14C-Quizartinib solution for infusion CI watch — Atom
- 14C-Quizartinib solution for infusion CI watch — JSON
- 14C-Quizartinib solution for infusion alone — RSS
Cite this brief
Drug Landscape (2026). 14C-Quizartinib solution for infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-quizartinib-solution-for-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab